AC Immune SA (ACIU) AI Stock Analysis

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. It specializes in discovering, designing, and developing medicines and diagnostics targeting neurodegenerative diseases tied to protein misfolding. Using its SupraAntigen and Morphomer platforms, the company creates vaccines, antibodies, and small molecules. Its pipeline includes Crenezumab, an antibody in Phase II prevention trials for Alzheimer's disease, as well as Phase II anti-Abeta vaccine candidate ACI-24 and anti-Tau vaccine candidate ACI-35. AC Immune also researches small molecule Tau aggregation inhibitors and diagnostic candidates targeting proteins such as TDP-43, alpha-synuclein, and NLRP3. It works with partners including Genentech, Biogen, Janssen Pharmaceuticals, Eli Lilly, Life Molecular Imaging, and WuXi Biologics.

AC Immune generates irregular revenue typical of clinical-stage biotechs. Annual revenue rose from $944,000 in FY2021 to $3.9M in FY2022, $14.8M in FY2023, and peaked at $27.3M in FY2024 before falling 86.9% to $3.6M in FY2025. Over the 5-year period from FY2020 to FY2025, revenue posted a CAGR of -25.4%. Net income remained negative in every period shown, including -$70.4M in FY2025 with an EPS of -$0.70. Research and development expenses were $56.4M in FY2025. Over the trailing twelve months ended June 30, 2026, revenue stood at $17.5M with a net profit margin of -246.5%, though quarterly revenue grew 1057.2% year-over-year in the latest quarter.

As of June 30, 2026, AC Immune reported $75.4M in cash and short-term investments alongside total debt of $4.1M, yielding net cash of $71.3M. Total assets were $150.4M against shareholders' equity of $35.2M. The company's current ratio was 0.93 and debt-to-equity stood at 0.12. Operating cash flow was -$66.1M in FY2025, leading to free cash flow of -$67.0M after capital expenditures of $859,541. Over 5 years, the company's share count increased 24.5%.

AC Immune closed at $2.39 on October 16, 2026, with a market capitalization of $237.6M and an enterprise value of $194.6M. The stock traded at a forward P/E of 16.6x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple was 13.6x, above the sector median of 4.1x, while its price-to-book ratio stood at 6.6x and EV-to-revenue was 9.1x. Over the past year, ACIU returned -19.3%, trailing the S&P 500 (SPY) return of 16.8%, and over five years it returned -61.3% versus 83.0% for the index.

Wall Street analysts hold 4 Strong Buy ratings on AC Immune, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $8.64, representing 261.4% upside versus the last close of $2.39. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.41 and revenue of $18.7M. For the following fiscal year, 3 analysts project revenue of $89.2M and an EPS of $0.50. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 3, 2026.

This page is an AI-written research summary of AC Immune SA (ACIU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ACIU income statement, ACIU balance sheet, ACIU key metrics, ACIU analyst forecast, ACIU chart. See the ACIU stock overview for the latest quote and news.